Previous 10 | Next 10 |
2023-04-18 12:50:32 ET Gainers: BELLUS Health ( BLU ) +98% . Dermata Therapeutics ( DRMA ) +68% . Gamida Cell ( GMDA ) +53% . Allarity Therapeutics ( ALLR ) +45% . Esports Entertainment Group ( GMBL ) +35% . Altamira Therapeu...
Trevi Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference PR Newswire Fireside chat will be held on Monday, April 17, 2023 , at 11:00 a.m. ET NEW HAVEN, Conn. , April 11, 2023 /PRNewswire/ -- Trevi Therapeutics, ...
2023-04-03 08:55:13 ET Summary In December of 2022 I introduced a number of stocks which I was adding to my "Tax Loss Selling Basket". In this article I summarize the logic and criteria for the basket. I then tally up the results including calculating overall returns and looki...
2023-03-16 23:10:04 ET Trevi Therapeutics, Inc. (TRVI) Q4 2022 Earnings Conference Call March 16, 2023 08:30 ET Company Participants Jennifer Good - President & Chief Executive Officer Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer...
2023-03-16 16:16:36 ET Trevi Therapeutics press release ( NASDAQ: TRVI ): Q4 GAAP EPS of -$0.06 beats by $0.03 . Ended 2022 with cash, cash equivalents, and marketable securities of $120.5 million. For further details see: Trevi Therapeutics GAAP EPS of -$0.0...
Trevi Therapeutics Announces Fourth Quarter and Year End 2022 Financial Results and Provides Business Update PR Newswire Multiple trial initiations planned for 2023 to progress Haduvio in chronic cough indications Management to host a conference call and webcast today ...
Trevi Therapeutics to Report Q4 and Year End 2022 Financial Results and Provide a Corporate Update on March 16, 2023 PR Newswire Conference call and webcast to be held at 4:30 p.m. EDT NEW HAVEN, Conn. , March 9, 2023 /PRNewswire/ -- Trevi Therapeut...
2023-03-08 08:46:06 ET Intelligent Bio Solutions ( INBS ) -48% on proposed public offering . Castor Maritime ( CTRM ) -36% . Miromatrix Medical ( MIRO ) -32% on pricing $10M stock offering . United Natural Foods ( UNFI ) -22% on Q2...
2023-03-08 07:45:29 ET Trevi Therapeutics ( NASDAQ: TRVI ) said the U.S. Patent and Trademark Office (USPTO) issued a notice of allowance for its application covering the use of Haduvio (nalbuphine ER) to treat chronic cough in idiopathic pulmonary fibrosis (IPF). The...
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis PR Newswire NEW HAVEN, Conn. , March 8, 2023 /PRNewswire/ -- Trevi T...
News, Short Squeeze, Breakout and More Instantly...
Trevi Therapeutics Inc. Company Name:
TRVI Stock Symbol:
NYSE Market:
Trevi Therapeutics Inc. Website:
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events PR Newswire Two abstracts accepted for oral presentation at the 13 th London International Cough Symposium NEW HAVEN, Conn. , July 2, 2024 /PRNewswire/ -- Trevi Therapeutic...
Trevi Therapeutics to Participate in Upcoming Conferences PR Newswire NEW HAVEN, Conn. , May 9, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™...
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates PR Newswire Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of...